Cargando…
Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665303/ http://dx.doi.org/10.1182/blood-2022-171001 |
| _version_ | 1784831262594170880 |
|---|---|
| author | Sannareddy, Aishwarya Reves, Heather Jaleta, Kefyalew .Ramiahsankarasubramanian, Ramyakumari Patel, Hetalkumari Narasimhan, Madhusudhanan Anderson, Larry D. Afrough, Aimaz Chung, Stephen S. Collins, Robert H. Kaur, Gurbakhash Kumar, Kiran A Madanat, Yazan F. Vusirikala, Madhuri Awan, Farrukh T. Muthukumar, Alagarraju Ramakrishnan Geethakumari, Praveen |
| author_facet | Sannareddy, Aishwarya Reves, Heather Jaleta, Kefyalew .Ramiahsankarasubramanian, Ramyakumari Patel, Hetalkumari Narasimhan, Madhusudhanan Anderson, Larry D. Afrough, Aimaz Chung, Stephen S. Collins, Robert H. Kaur, Gurbakhash Kumar, Kiran A Madanat, Yazan F. Vusirikala, Madhuri Awan, Farrukh T. Muthukumar, Alagarraju Ramakrishnan Geethakumari, Praveen |
| author_sort | Sannareddy, Aishwarya |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9665303 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The American Society of Hematology. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96653032022-11-16 Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience Sannareddy, Aishwarya Reves, Heather Jaleta, Kefyalew .Ramiahsankarasubramanian, Ramyakumari Patel, Hetalkumari Narasimhan, Madhusudhanan Anderson, Larry D. Afrough, Aimaz Chung, Stephen S. Collins, Robert H. Kaur, Gurbakhash Kumar, Kiran A Madanat, Yazan F. Vusirikala, Madhuri Awan, Farrukh T. Muthukumar, Alagarraju Ramakrishnan Geethakumari, Praveen Blood Poster Abstracts The American Society of Hematology. Published by Elsevier Inc. 2022-11-15 2022-11-15 /pmc/articles/PMC9665303/ http://dx.doi.org/10.1182/blood-2022-171001 Text en Copyright © 2022 The American Society of Hematology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Poster Abstracts Sannareddy, Aishwarya Reves, Heather Jaleta, Kefyalew .Ramiahsankarasubramanian, Ramyakumari Patel, Hetalkumari Narasimhan, Madhusudhanan Anderson, Larry D. Afrough, Aimaz Chung, Stephen S. Collins, Robert H. Kaur, Gurbakhash Kumar, Kiran A Madanat, Yazan F. Vusirikala, Madhuri Awan, Farrukh T. Muthukumar, Alagarraju Ramakrishnan Geethakumari, Praveen Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience |
| title | Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience |
| title_full | Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience |
| title_fullStr | Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience |
| title_full_unstemmed | Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience |
| title_short | Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience |
| title_sort | do monoclonal antibody therapies improve 'real-world' outcomes of covid-19 in patients with lymphoid malignancies? the ut southwestern experience |
| topic | Poster Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665303/ http://dx.doi.org/10.1182/blood-2022-171001 |
| work_keys_str_mv | AT sannareddyaishwarya domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT revesheather domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT jaletakefyalew domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT ramiahsankarasubramanianramyakumari domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT patelhetalkumari domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT narasimhanmadhusudhanan domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT andersonlarryd domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT afroughaimaz domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT chungstephens domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT collinsroberth domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT kaurgurbakhash domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT kumarkirana domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT madanatyazanf domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT vusirikalamadhuri domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT awanfarrukht domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT muthukumaralagarraju domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience AT ramakrishnangeethakumaripraveen domonoclonalantibodytherapiesimproverealworldoutcomesofcovid19inpatientswithlymphoidmalignanciestheutsouthwesternexperience |